Functional Relevance of Protein Glycosylation to the Pro-Inflammatory Effects of Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) on Monocytes/Macrophages

Heng Ge1, Wei Yuan1†, Jidong Liu2, Qing He1, Song Ding1, Jun Pu1*, Ben He1*

1 Department of Cardiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 2 Department of Cardiac Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

† Current address: Department of Cardiology, Jiangsu University Affiliated Hospital, Jiangsu Province, China

* heben@medmail.com.cn (BH); pujun310@hotmail.com (JP)

Abstract

Background and Objective
Extracellular matrix metalloproteinase inducer (EMMPRIN) is an important pro-inflammatory protein involved in the cellular functions of monocytes/macrophages. We have hypothesized that high-level heterogeneousness of protein glycosylation of EMMPRIN may have functional relevance to its biological effects and affect the inflammatory activity of monocytes/macrophages.

Methods
The glycosylation patterns of EMMPRIN expressed by monocytes/macrophages (THP-1 cells) in response to different extracellular stimuli were observed, and the structures of different glycosylation forms were identified. After the purification of highly- and less-glycosylated proteins respectively, the impacts of different glycosylation forms on the pro-inflammatory effects of EMMPRIN were examined in various aspects, such as cell adhesion to endothelial cells, cell migrations, cytokine expression, and activation of inflammatory signalling pathway.

Results
1) It was mainly the highly-glycosylated form of EMMPRIN (HG-EMMPRIN) that increased after being exposed to inflammatory signals (PMA and H2O2). 2) Glycosylation of EMMPRIN in monocytes/macrophages led to N-linked-glycans being added to the protein, with the HG form containing complex-type glycans and the less-glycosylated form (LG) the simple type. 3) Only the HG-EMMPRIN but not the LG-EMMPRIN exhibited pro-inflammatory effects and stimulated inflammatory activities of the monocytes/macrophages (i.e., activation of ERK1/2...
and NF-κB pathway, enhanced monocyte-endothelium adhesion, cell migration and matrix metalloproteinase -9 expression).

**Conclusions**

Post-transcriptional glycosylation represents an important mechanism that determines the biological effects of EMMPRIN in monocytes/macrophages. Glycosylation of EMMPRIN may serve as a potential target for regulating the inflammatory activities of monocytes/macrophages.

**Introduction**

Inflammation is a key driving force in the pathophysiological process of many diseases, where activated monocytes/macrophages play a significant role [1–3]. Extracellular matrix metalloproteinase inducer (EMMPRIN)[4] is a transmembrane glycoprotein belonging to the immunoglobulin superfamily[5], originally identified as a surface protein of tumour cells that can stimulate the expression of matrix metalloproteinases (MMPs) in fibroblasts[6–8]. The implication of EMMPRIN in the activity of monocytes/macrophages has also been suggested. For instance, in a study on atherosclerosis, a well-recognized inflammatory disease[9], EMMPRIN expression found in human atheroma was mainly induced by monocytes/macrophages[4,10]. The functional roles of EMMPRIN in monocytes/macrophages seem to be well beyond stimulating MMPs, which may also include enhancing cell adhesion as well as migration into inflammation-involved tissues [11,12]—subsequent to the activation of inflammatory intercellular signal pathway, such as mitogen-activated protein kinases (MAPK) and NF-κB[12]. EMMPRIN is therefore considered an important protein involved in the inflammatory activity of monocytes/macrophages.

One of the most striking features of EMMPRIN is its heterogeneous glycosylation forms. The molecular weights of the protein can vary greatly, even to a difference of ~30 kDa between a highly-glycosylated (HG) and a less-glycosylated (LG) form[5]. Results from studies on tumour cells show that both HG- and LG-EMMPRIN are characterized by N-linked glycosylation [13–15]. However, the glycan structures can differ: the LG form comprises simple-type glycans of a high-mannose composition, while the HG form features a complex-type carbohydrate structure[13,14]. The heterogeneous glycosylation of EMMPRIN has also been observed in monocytes/macrophages[16]. In vitro experiments have revealed significant increases of HG-EMMPRIN during monocytes’ differentiation into macrophages[16].

Differentiated glycosylation of EMMPRIN exhibits functional relevance in tumor cells. For instance, caveolin, a scaffolding protein composing the caveolae membrane, was shown to mediate tumour-suppressing effects by being selectively associated with LG-EMMPRIN but not HG-EMMPRIN [13]. The functional difference between HG- and LG-EMMPRIN in monocytes/macrophages has also been implied. Sluijter and colleagues [17], by examining carotid atherosclerotic specimens, once reported that HG-EMMPRIN was highly associated with unstable lesion whereas LG-EMMPRIN was abundantly present with stable plaques, indicating that different glycosylation forms expressed by monocytes/macrophages are related to plaque characteristics.

Notwithstanding, to our best knowledge, there is still a lack of research specifically focusing on the “biological meaning” of EMMPRIN glycosylation in monocytes/macrophages. Since the pro-inflammatory effects of EMMPRIN have largely been proved, the knowledge of
the post-transcriptional modification, glycosylation, of this protein leading to functional implications of inflammatory cells requires to be unravelled.

From this background, the present study aims to: i) identify the expression patterns and structural differences of glycosylation forms of EMMPRIN in monocytes/macrophages; ii) elucidate the functional impacts of the EMMPRIN glycosylation forms on the inflammatory activity of monocytes/macrophages.

**Methods**

**Reagents**

Fetal bovine serum (FBS) and Medium 199 (M-199) were purchased from Gibco BRL (Life Technologies, NY). Phorbol 12-myristate 13-acetate (PMA), H$_2$O$_2$, peptide-N-glycosidase F (PNGase F), swainsonine, calcein-AM and Coomassie blue were acquired from Sigma-Aldrich (St. Louis, MO); Endoglycosidase H (Endo H) from Hoffmann-La Roche (Basel Switzerland); TNF-α from eBioscience (San Diego, CA); PD98059 from Cell Signaling (Danvers, MA). For protein purification, the Immunopure rprotein A IgG plus orientation Kit and the silver staining kit were provided by Pierce (Rockford, IL); and the monoclonal antibody against EMMPRIN (mAb-EMMPRIN) was produced by Genscript Corporation (Nanjing, China). For Western blot, the protein extraction kit was acquired from Beyotime (Haimen, China); mouse monoclonal antibodies against EMMPRIN, pERK1/2, pIκBα, ERK1/2, IκBα and rabbit polyclonal antibodies against MMP9 from Abcam (Cambridge, MA); the mouse monoclonal antibody against β-actin from Santa Cruz (Dallas, Tex).

**Cell cultures**

The human monocytic cell line, THP-1 and human umbilical vein cells (HUVECs) were acquired from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. The THP-1 cells were cultured in the RPMI 1640 medium supplemented with 10% FBS, 10 mM HEPES, 10,000 U/ml penicillin and 10 mg/ml streptomycin, while HUVECs were grown in M-199 medium containing 10% FBS and antibiotics. Both were maintained at 37°C in a 5% CO$_2$ incubator.

**Purification of EMMPRIN**

EMMPRIN was purified from the membrane fraction of THP-1 cell by immunoaffinity chromatography using mAb-EMMPRIN as previously described[15]. The THP-1 cells were stimulated with PMA (100 ng/ml) for 24 hours, after which, the cell membranes were extracted using the membrane protein extraction kit according to the manufacturer’s instructions. The supernatants of the extracts were applied to an immunoaffinity column which was coupled with mAb-EMMPRIN, and further stabilized with homobifunctional NHS-ester cross-linker DSS (all done according to the manufacturer’s instructions).

After recirculating the sample through the column for 12 hours at 4°C, the column was washed with Binding/Wash Buffer for three times, and the EMMPRIN protein was then eluted from the column with a solution of 50 mM diethylamine and 30 mM octylglucoside (pH 11.5). The eluted protein was immediately neutralized with 0.5 M NaH$_2$PO$_4$ followed by dialyzed (0.01 M PBS, pH 7.4) and lyophilized.

The purified protein was defined as highly glycosylated (HG-EMMPRIN). LG-EMMPRIN was derived by treating HG-EMMPRIN (100 μg/ml) with PNGase F (0.1 U) for 24 hours. Both HG-EMMPRIN and LG-EMMPRIN were verified by silver stained SDS-PAGE (12%) and Western blot assay.
Western blot

After different treatments, THP-1 cells were rinsed with PBS and lysed with lysis buffer (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 2x protease inhibitor mix). Cell lysates were separated by SDS-PAGE and transferred to PVDF membrane. After being blocked for 1 hour with 5% non-fat milk in TBS-T (Tris-buffered saline containing 0.1% Tween 20), the PVDF membrane was incubated with the primary antibody, followed by the secondary antibody. The blots were detected using the ECL Plus Western blotting detection system (GE Healthcare).

Cell adhesion assay

HUVECs were stimulated with 10 ng/ml TNF-α for 6 hours. After dedicated treatments, THP-1 cells were stained with 5 mol/l calcein-AM at 37°C for 30 minutes before being added onto the HUVEC monolayers at a density of 10⁶ cells/ml. After 30 minutes, non-adherent monocytes were washed off. The attached monocytes were quantified by averaging the numbers of cells counted from six randomly selected optical fields under fluorescent microscopy for each treatment.

Cell migration assay

The differently treated THP-1 cells were cultured in non-FBS medium in the upper chamber of the transwell insert (8μm pore size, BD) with a density of 1×10⁶ per well. The RPMI 1640 medium supplemented with 10% FBS was added to the wells below, which constituted the lower chambers of the chemotaxis assay.

After an incubation at 37°C in 5% CO₂ for 6 hours, the filters were removed and the cells were stained by Giemsa stain. Cells were quantified by averaging the numbers counted from 6 high-power fields (200× magnification)

Gelatin zymography

MMP activities were determined by gelatin zymography. 10⁶ cells were seeded in 60mm culture dishes with 3 ml culture medium. After 24 hours, cell-free cultural media were collected for assay. Each sample (30 μl) was resolved by SDS-PAGE using 10% polyacrylamide gel containing 0.1% gelatin. The gels were washed twice in 2.5% (w/v) Triton X-100 for 30 minutes and then incubated for 20 hours with a reaction buffer containing 50 mM Tris, 0.2 mM NaCl, 5 mM anhydrous CaCl₂ and 2.5% Triton X-100. Afterwards, the gels were stained with 0.5% (w/v) Coomassie blue (R-250), and destained with a buffer consisting of 20% methanol, 10% acetic acid and 70% distilled water for 30 minutes, in order to visualize the zymogen bands. Finally, the zymography gels were scanned and analysed using special software (National Institutes of Health, USA).

Statistical analysis

Data were expressed as Mean±S.E.M. Statistical analysis was performed by using one-way ANOVA test, the difference between specific group and the control group was then analysed using Student Newman Keuls Test, a p value < 0.05 was considered to be statistically significant. SPSS software version 22.0 (SPSS, Inc., Chicago, IL) was employed.
Results

Characterization of glycosylation forms of EMMPRIN in monocytes/macrophages

The HG-EMMPRIN purified from the THP-1 cells was subjected to digestion by two types of endoglycosidases: PNGase F and Endo H\[18\], for that the former is capable of removing complex-type N-linked glycans from glycoproteins and the latter specifically target at simple-type N-linked glycans. After digestion by PNGase F, HG-EMMPRIN was no longer detectable; by contrast, Endo H mediated little effect on the presence of HG-EMMPRIN. (Fig. 1A). Such results can indicate that HG-EMMPRIN is mainly composed of complex-type, N-linked glycans.

To confirm our finding, we pre-treated THP-1 cells with swainsonine, an inhibitor of α-mannosidase being capable of preventing the formation of complex-type oligosaccharides for glycoprotein[19]. When HG-EMMPRIN expression was enhanced of by PMA induction, this expression significantly declined, in a concentration-dependent manner, with the treatment of swainsonine, (Fig. 1B and 1C). Interestingly, an inverse increase in LG-EMMPRIN expression was concurrently observed.

Changing patterns of EMMPRIN glycosylation in monocytes/macrophages

To illustrate the changes in the glycosylation pattern of EMMPRIN in monocytes in response to extracellular stimuli, we monitored the expression levels of HG- and LG-EMMPRIN when the cells were exposed to PMA and H₂O₂, respectively. Previous reports have indicated that PMA can activate monocytes, resulting in their differentiation into macrophages, during which the expression of EMMPRIN can be greatly enhanced[16,20]. In our current study, it was mainly the expression of HG-EMMPRIN that increased, with little change identified in LG-EMMPRIN expression, and such an increase seemed to observe in both a concentration-dependent and a time-dependent way in response to PMA stimulation (Fig. 2, A and B). Similarly, after being treated with H₂O₂ (i.e. a stimulus of oxidative stress, another key pro-inflammatory factor activating monocytes[21]), the HG-EMMPRIN expression of the cells was also significantly increased, whereas the LG-EMMPRIN expression exhibited no difference (Fig. 2C and D). These results purport that HG-EMMPRIN is more responsive to inflammatory signals than the LG form in monocytes.

Functional relevance of EMMPRIN glycosylation to inflammatory activities of monocytes/macrophages

In light of the fact that the glycosylation pattern of EMMPRIN in monocytes alters when activated by inflammatory signals, we furthered our study to investigate whether HG-EMMPRIN and LG-EMMPRIN can differently regulate the inflammatory activity of monocytes/macrophages. To do so, we examined several aspects of cellular functionality relating to inflammatory activities: i.e. adhesion to the vascular endothelium, cell migration and MMP-9 production.

In the monocytes-endothelium adhesion test, where the adhesion of THP-1 cells to HUVECs (as mediated by TNF-α)[22] was assessed, the treatment of HG-EMMPRIN (100μg/ml for 24 hours) led to a significantly higher number of cells attached than that resulting from the treatment of LG-EMMPRIN (100μg/ml for 24 hours) and the control (culture medium) (Fig. 3). LG-EMMPRIN treatment did not result in an increased number of attached cells when compared with the control.

In another experiment, the Boyden chamber assay[23] was applied to assess the migratory capability of THP1 cells corresponding to different glycosylation patterns of EMMPRIN. The
Fig 1. Characterization of glycosylation patterns of EMMPRIN in THP-1 cells. A: A representative Western blot of 3 independent experiments reveals two differently glycosylated EMMPRIN proteins from THP-1 cell, which refer to HG-EMMPRIN (with larger molecular weight) and LG-EMMPRIN (with smaller molecular weight). The protein glycosylation had different response to the treatment of PNGase F or Endo H. B: A representative Western blot demonstrates that the expression of HG-EMMPRIN by THP-1 cells responsive to PMA induction was inhibited by swainsonine. C: Quantitative analysis of 3 independent experiments probing the change of HG-EMMPRIN (upper figure) and LG-EMMPRIN (lower figure) in response to PMA and swainsonine. The band intensity was normalized to that of the β-actin. *P < 0.05, compared with the control group (whose value was set as 1.0). doi:10.1371/journal.pone.0117463.g001
cells were examined under the condition of LG-EMMPRIN treatment (100μg/ml), HG-EMMPRIN treatment (100μg/ml), or the control (culture medium). It was observed that the treatment of HG-EMMPRIN significantly enhanced the migration of THP-1 cells, while the LG-EMMPRIN treatment seemed to lack such an effect—with a level of migration comparable to that of the control (Fig. 4).

The next step was to identify whether glycosylation of EMMPRIN can also influence MMP expression in monocytes/macrophages. MMP-9 expression by monocytes is closely associated with the inflammatory effects of monocytes/macrophages (i.e. progression and instability of

---

Fig 2. Changing of EMMPRIN glycosylation in response to pro-inflammatory stimuli in THP-1 cells. A representative Western blot demonstrates the changing of EMMPRIN glycosylation in response to PMA (A and B) or H2O2 (C and D) both in a concentration and time-dependent manner. Quantitative analysis of 3 independent experiments is shown for each treatment. The band intensity was normalized to that of β-actin. *P < 0.05, compared with the control group (whose value was set as 1.0). doi:10.1371/journal.pone.0117463.g002
**Fig 3. The impact of EMMPRIN glycosylation on monocytes-endothelium adhesion.** A: Representative sections demonstrating the adhesive capabilities of fluorescently labelled THP-1 cells to the HUVEC monolayer when treated with HG-EMMPRIN (with or without pre-treatment of PD98059), LG-EMMPRIN or the control medium. B: Quantification of adhesive cell numbers of 3 independent experiments. *P < 0.05, compared with the control group.

doi:10.1371/journal.pone.0117463.g003

**Fig 4. The impact of EMMPRIN glycosylation on monocytes migration.** A: Representative sections demonstrating migratory activities of THP-1 cells in response to the treatment of HG-EMMPRIN (with or without pre-treatment of PD98059), LG-EMMPRIN or the control medium, respectively, as measured by the Boyden chamber assay. B: Quantification of migratory cell numbers of 3 independent experiments. *P < 0.05, compared with the control group.

doi:10.1371/journal.pone.0117463.g004
atherosclerotic plaque)[24] and can be induced by EMMPRIN[25]. Our Western blot analysis detected a remarkable increase of MMP-9 from the supernatants of the HG-EMMPRIN-treated cells (100 μg/ml for 24 hours), compared with those treated with LG-EMMPRIN (100 μg/ml for 24 hours) or the control (culture medium) (Fig. 5A). No difference between the MMP-9 levels was observed between the cells treated with LG-EMMPRIN and the control. In a similar way, gelatine zymography identified a higher level of MMP-9 activity from the cells treated with HG-EMMPRIN, whereas the activity exhibited by the cells treated with LG-EMMPRIN was comparable to that of the control (Fig. 5B). In the meanwhile, the expression of MMP-2, a type of MMP not responsive to EMMPRIN induction, was neither affected by HG-EMMPRIN treatment nor by LG-EMMPRIN treatment.

HG-EMMPRIN activates the pro-inflammatory ERK/NF-κB signalling pathway

It is conceivable that the inflammatory activities of monocytes/macrophages are driven by activation of intracellular pro-inflammatory signalling pathways. Our previous studies have highlighted the relationship between EMMPRIN and the activation of ERK/NF-κB pathway in monocytes/macrophages[12,26]. Therefore, we were interested to know whether the previous findings could be attributed to the glycosylation of EMMPRIN resulting in the activation of the signalling pathways. To do so, we examined the levels of phosphorylated ERK1/2 (i.e. pERK1/2) and phosphorylated IκBα (i.e. pIκBα) in THP-1 cells. While the former can indicate the levels of activated MAPK per se, the latter refers to the degradation of a key inhibitor of NF-κB and hence the activation of NF-κB[27]. Unsurprisingly, higher levels of both phosphorylated forms were found by Western blot in the cells treated with HG-EMMPRIN (100 μg/ml for 24 hours), in comparison...
with the phosphorylation levels observed in the LG-EMMPRIN (100 μg/ml for 24 hours) treated cells which were just comparable to those of the controls (culture medium) (Fig. 6).

Addition of an MEK inhibitor, PD98059, to the cells further verified the critical role of HG—EMMPRIN in activating the ERK/NF-κB pathway. As such, pre-treatment of PD98059 (50 μM, 2 hours) inhibited the elevated levels of phosphorylation of ERK1/2 and IκBα, and, in the meanwhile, significantly attenuated the enhanced monocyte-endothelium adhesion, monocyte migration and MMP-9 expression that were responding to the treatment of HG-EMMPRIN (Figs. 3–6).

Discussion

In this study, we have identified a posttranslational modification mechanism, i.e. glycosylation, of the transmembrane protein EMMPRIN that underlies its functional role in inflammation. We have demonstrated that the highly-glycosylated form of EMMPRIN rather than its less-glycosylated form is associated with heightened inflammatory responses by monocytes/macrophages. We have further illustrated that the HG-form is essential for EMMPRIN to drive the inflammatory activity of monocytes/macrophages by activating intracellular pro-inflammatory signalling and subsequently enhancing cell adhesion, cell migration and MMP-9 production. This is the first study to date that systemically differentiates the biological functions of heterogeneous glycosylation forms of EMMPRIN in monocytic cells.

Both laboratory and clinical studies have previously indicated the implication of EMMPRIN in diseases driven by the inflammatory activities of monocytes/macrophages. For instance,
Schmidt and colleagues have linked EMMPRIN to the development of atherosclerosis by demonstrating an upregulation of EMMPRIN expression in circulating monocytes among patients with acute myocardial infarction (a severe clinical setting usually caused by inflammation-provoked plaque rupture[25]). A potential mechanism has been suggested, which points to the key roles this molecule play in recruiting monocytes/macrophages into atherosclerotic lesions and enhancing their inflammatory activities[10,11,16,25]. Our previous results also showed that EMMPRIN expression was enhanced during monocytes’ differentiation into macrophages[16,20], and the suppression of EMMPRIN expression was paralleled by significantly reduced inflammatory activity of monocytes/macrophages[12].

However, the preceding studies were mostly focused on EMMPRIN per se, without probing into the functional relevance of its glycosylation variation, in spite of its well-observed structural differences. The only clue to the implication of differentially glycosylated EMMPRIN in monocytes/macrophage-induced inflammatory disease was derived from Sluijter and colleagues’ work[17], which linked HG-EMMPRIN with atherosclerotic plaque instability. Their findings are in line with our current results, in that: i) inflammatory or oxidative stress, two specific micro-surroundings within advanced or unstable lesions, can significantly increase HG-EMMPRIN in monocytes/macrophages. ii) HG-EMMPRIN but not LG-EMMPRIN is associated with an enhanced monocytic inflammatory activity that may lead to plaque instability.

The importance of the glycosylation of EMMPRIN in exerting its pro-inflammatory effects in monocytes/macrophages has been systematically investigated by our study. The HG form seems to be essential for EMMPRIN to mediate key aspects of inflammatory activity of monocytes/macrophages[29–31]. In our study, the cells stimulated by HG-EMMPRIN were better able to adhere to the vascular endothelium and migrate towards pro-inflammatory stimuli; and they also exhibited enhanced expression of inflammatory cytokines such as MMP-9. On the contrary, the effects of LG-EMMPRIN were only comparable to the control. Being consistent with previous findings that implicated the roles of ERK and NF-κB in pro-inflammatory signalling of EMMPRIN[12,26,32], we have further proved that it is the HG form of EMMPRIN but not the LG form that can activate these signalling pathways, accounting for the induction of inflammatory activity of monocytes/macrophages by EMMPRIN.

Among all the findings of this study is the confirmation of the glycosylation structures of EMMPRIN in monocytes/macrophages. Similar to what were observed in tumour cells[13–15], the glycosylation forms are characterized by N-glycosylation, and the HG-form comprises complex-type carbohydrates and the LG-form contains simple-type glycans. Although the results were well expected, this knowledge can still yield important insights. It is not far-fetched to consider the complex type of N-glycosylated EMMPRIN as a potential target for inhibition of the over-activated inflammatory activity of monocytes/macrophages, from which new therapeutics employing cutting-edge glycoengineering technologies may arise[33,34].

**Conclusion**

The highly-glycosylated form is essential for EMMPRIN protein to exert its pro-inflammatory effects in monocytes/macrophages. The glycosylation of EMMPRIN in monocytes/macrophages can be considered a potential target for development of new therapeutics that is able to inhibit over-activated inflammatory activity of monocytes/macrophages.

**Acknowledgments**

We are grateful to Dr. Bingshi Guo for benefiting from his suggestions and insights on the study.
Author Contributions
Conceived and designed the experiments: HG WY JP. Performed the experiments: HG JDL QH. Analyzed the data: HG WY QH. Contributed reagents/materials/analysis tools: SD. Wrote the paper: HG JP BH.

References
1. Hansson GK (2009) Atherosclerosis—an immune disease: The Anitschkov Lecture 2007. Atherosclerosis 202: 2–10. doi: 10.1016/j.atherosclerosis.2008.08.039 PMID: 18951547
2. Galkina E, Ley K (2009) Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 27: 165–197. doi: 10.1146/annurev.immunol.021908.132620 PMID: 19302038
3. Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullesstad L, et al. (2008) Atheroerotic plaque stability—what determines the fate of a plaque? Prog Cardiovasc Dis 51: 183–194. doi: 10.1016/j.pcad.2008.09.001 PMID: 19026853
4. Yoon YW, Kwon HM, Hwang KC, Choi EY, Hong BK, et al. (2005) Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis 180: 37–44. PMID: 15823273
5. Iacono KT, Brown AL, Greene MI, Saouaf SJ (2007) CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol 83: 283–295. PMID: 17945211
6. Muramatsu T, Miyachi T (2003) Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol Histopathol 18: 981–987. PMID: 12792908
7. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, et al. (1995) The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55: 434–439. PMID: 7812975
8. Li R, Huang L, Guo H, Toole BP (2001) Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fibroblasts. J Cell Physiol 186: 371–379. PMID: 11169976
9. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868–874. PMID: 12490960
10. Major TC, Liang L, Lu X, Rosebury W, Bocan TM (2002) Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 22: 1200–1207. PMID: 12117738
11. Schulz C, von Bruhl ML, Barocke V, Cullen P, Mayer K, et al. (2011) EMMPRIN (CD147/basigin) mediates platelet-monocyte interactions in vivo and augments monocyte recruitment to the vascular wall. J Thromb Haemost 9: 1007–1019. doi: 10.1111/j.1538-7836.2011.04235.x PMID: 21320284
12. Yuan W, Ge H, He B (2010) Pro-inflammatory activities induced by CyPA-EMMPRIN interaction in monocytes. Atherosclerosis 213: 415–421. doi: 10.1016/j.atherosclerosis.2010.09.033 PMID: 21035802
13. Tang W, Chang SB, Hemler ME (2004) Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell 15: 4043–4050. PMID: 15201341
14. Huang W, Luo WJ, Zhu P, Tang J, Yu XL, et al. (2013) Modulation of CD147-induced matrix metalloproteinase activity: role of CD147 N-glycosylation. Biochem J 449: 437–448. doi: 10.1042/BJ20120343 PMID: 23005037
15. Yu XL, Jiang JL, Li L, Feng Q, Xu J, et al. (2006) The glycosylation characteristic of hepatoma-associated antigen HAb18G/CD147 in human hepatoma cells. Int J Biochem Cell Biol 38: 1939–1945. PMID: 16824781
16. Zhang J, Ge H, Wang C, Guo TB, He Q, et al. (2007) Inhibitory effect of PPAR on the expression of EMMPRIN in macrophages and foam cells. Int J Cardiol 117: 373–380. PMID: 16860414
17. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, et al. (2006) Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 37: 235–239. PMID: 16339461
18. Maley F, Trimble RB, Tarentino AL, Plummer TH Jr (1989) Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal Biochem 180: 195–204. PMID: 25105451
19. Elbein AD, Solf R, Dorling PR, Vosbeck K (1981) Swainsonine: an inhibitor of glycoprotein processing. Proc Natl Acad Sci U S A 78: 7393–7397. PMID: 6801650
20. Ge H, Zhang JF, Guo BS, He Q, Wang BY, et al. (2007) Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma. Vascul Pharmacol 46: 114–121. PMID: 17055343
21. Gough DR, Cotter TG (2011) Hydrogen peroxide: a Jekyll and Hyde signalling molecule. Cell Death Dis 2: e213. doi: 10.1038/cddis.2011.96 PMID: 21975295
22. Narizhneva NV, Razorenova OV, Podrez EA, Chen J, Chandrasekharan UM, et al. (2005) Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J 19: 1158–1160. PMID: 15833768
23. Chen HC, editor (2005) Boyden chamber assay. New Jersey: Humana Press. 15–22 p.
24. Galis ZS, Sukhova GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94: 2493–2503. PMID: 7989608
25. Schmidt R, Buttman A, Ungerer M, Joghetaei N, Bulbul O, et al. (2006) Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 113: 834–841. PMID: 16461815
26. Huang Z, Wang C, Wei L, Wang J, Fan Y, et al. (2008) Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res Commun 374: 517–521. doi: 10.1016/j.bbrc.2008.07.058 PMID: 18647594
27. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S (1995) Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 9: 2723–2735. PMID: 7590248
28. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 92: 7686–7689. PMID: 7644477
29. Newby AC (2008) Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 28: 2108–2114. doi: 10.1161/ATVBAHA.108.173898 PMID: 18772495
30. Chi Z, Melendez AJ (2007) Role of cell adhesion molecules and immune-cell migration in the initiation, onset and development of atherosclerosis. Cell Adh Migr 1: 171–175. PMID: 19262139
31. Pamukcu B, Lip GY, Devitt A, Griffiths H, Shantsila E (2010) The role of monocytes in atherosclerotic coronary artery disease. Ann Med 42: 394–403. doi: 10.3109/07853890.2010.497767 PMID: 20568979
32. Kim JY, Kim WJ, Kim H, Suk K, Lee WH (2009) The Stimulation of CD147 Induces MMP-9 Expression through ERK and NF-kappaB in Macrophages: Implication for Atherosclerosis. Immune Netw 9: 90–97. doi: 10.4110/in.2009.9.3.90 PMID: 20107538
33. Sinclair AM, Elliott S (2005) Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 94: 1626–1635. PMID: 15959862
34. Sola RJ, Griebenow K (2010) Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 24: 9–21. doi: 10.2165/11530550-000000000-00000 PMID: 2055529